Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2009

Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors: Gerald Antoch, Andreas Bockisch

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2009

Abstract

Introduction

Hybrid imaging systems providing morphological and functional data in a single session have been available for oncological imaging for some time. So far, computed tomography (CT) has been the morphological method-of-choice for inclusion into these hybrid imaging systems. However, recently, research has focused on hardware-based fusion of function with magnetic resonance imaging (MRI) rather than CT.

Objectives

Now that the first head-only positron emission tomography (PET)/MRI systems have been installed and whole-body systems are to be expected in the near future, potential indications in clinical oncology have to be addressed.

Discussion

This article discusses potential indications of PET/MRI in whole-body oncology imaging. Potential advantages and disadvantages compared with currently available hybrid imaging systems will be reviewed.

Haberkorn U, Schoenberg SO. Imaging of lung cancer with CT, MRT and PET. Lung Cancer 2001;34(Suppl 3):S13–23.PubMedCrossRef

Hoh CK. Clinical use of FDG PET. Nucl Med Biol 2007;34(7):737–42.PubMedCrossRef

Collins CD. PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging 2007;7(Spec No A):S77–87.PubMedCrossRef

Antoch G, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22(21):4357–68.PubMedCrossRef

Freudenberg LS, et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14(11):2092–8.PubMedCrossRef

Freudenberg LS, et al. Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 2004;49(5):537–40.PubMed

Bar-Shalom R, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44(8):1200–9.PubMed

Pichler BJ, Judenhofer MS, Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 2008;(185 Pt 1):109–32.CrossRef

Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol 2008;18(6):1077–86.PubMedCrossRef

10.

Pichler BJ, et al. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med 2008;38(3):199–208.PubMedCrossRef

11.

Pauls S, et al. Improved non-invasive T-staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin 2007;46(1):9–14. quiz N1–2.PubMed

12.

Babin E, et al. PET/CT for assessing mandibular invasion by intraoral squamous cell carcinomas. Clin Otolaryngol 2008;33(1):47–51.PubMedCrossRef

13.

Veit-Haibach P, et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006;296(21):2590–600.PubMedCrossRef

14.

Lee BY, et al. Various image findings of skeletal muscle metastases with clinical correlation. Skeletal Radiol 2008;37:923–8.PubMedCrossRef

15.

Shah GV, et al. New directions in head and neck imaging. J Surg Oncol 2008;97(8):644–8.PubMedCrossRef

16.

Fahlbusch R, Samii A. A review of cranial imaging techniques: potential and limitations. Clin Neurosurg 2007;54:100–4.PubMed

17.

Van Goethem M, et al. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol 2006;32(9):901–10.PubMedCrossRef

18.

Willatt JM, et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247(2):311–30.PubMedCrossRef

19.

Ba-Ssalamah A, et al. Magnetic resonance imaging of liver malignancies. Top Magn Reson Imaging 2007;18(6):445–55.PubMedCrossRef

20.

King AD, et al. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol 2008;81(964):291–8.PubMedCrossRef

21.

Heusner TA, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol 2008; 81(969):743–8.PubMedCrossRef

22.

Heusner TA, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49:1215–2.PubMedCrossRef

23.

Maderwald S, et al. To TOF or not to TOF: strategies for non-contrast-enhanced intracranial MRA at 7 T. Magma 2008;21(1–2):159–67.PubMedCrossRef

24.

Antoch G, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290(24):3199–206.PubMedCrossRef

25.

Schmidt GP, et al. Comparison of high resolution whole-body MRI using parallel imaging and PET-CT. First experiences with a 32-channel MRI system. Radiologe 2004;44(9):889–98.PubMedCrossRef

26.

Deslauriers J, Gregoire J. Clinical and surgical staging of non-small cell lung cancer. Chest 2000;117(4 Suppl 1):96S–103S.PubMedCrossRef

27.

Staples CA, et al. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 1988;167(2):367–72.PubMed

28.

Turkington TG, et al. Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces. J Comput Assist Tomogr 1995;19(1):117–24.PubMedCrossRef

29.

Barentsz JO, Futterer JJ, Takahashi S. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol 2007;63(3):369–72.PubMedCrossRef

30.

Saksena MA, Saokar A, Harisinghani MG. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging. Eur J Radiol 2006;58(3):367–74.PubMedCrossRef

31.

Squillaci E, et al. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT-initial clinical experience. Abdom Imaging. 2008; in press.

32.

Schmidt GP, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008;65(1):47–58.PubMedCrossRef

33.

Pfannenberg C, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43(3):557–64.PubMedCrossRef

34.

Schmidt GP, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17(4):939–49.PubMedCrossRef

35.

Eustace SJ, et al. Whole-body MR imaging. Practical issues, clinical applications, and future directions. Magn Reson Imaging Clin N Am 1999;7(2):209–36.PubMed

36.

Antoch G, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005;46(3):520–5.PubMed

37.

Kleis M, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging. 2008; in press.

Title: Combined PET/MRI: a new dimension in whole-body oncology imaging?
Authors: Gerald Antoch
Andreas Bockisch
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0951-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combined PET/MRI: a new dimension in whole-body oncology imaging?

Abstract

Introduction

Objectives

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objectives

Discussion

Please log in to get access to this content

Other articles of this Special Issue 1/2009

PET/MRI system design

Magnetic resonance imaging methodology

Novel detector technology for clinical PET

PET and MRI in cardiac imaging: from validation studies to integrated applications

A decade of combined imaging: from a PET attached to a CT to a PET inside an MR

Risks and safety aspects related to PET/MR examinations